Daniel Bruno - Genmab AS Director, Employee Representative
| GMAB Stock | DKK 1,926 98.50 4.86% |
Insider
Daniel Bruno is Director, Employee Representative of Genmab AS since 2016.
| Age | 39 |
| Tenure | 8 years |
| Phone | (45) 70 20 27 29 |
| Web | www.genmab.com |
Genmab AS Management Efficiency
The company has return on total asset (ROA) of 0.1029 % which means that it generated a profit of $0.1029 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2359 %, meaning that it generated $0.2359 on every $100 dollars invested by stockholders. Genmab AS's management efficiency ratios could be used to measure how well Genmab AS manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Martin Barlebo | Orsted AS | 52 | |
| Morten Dyrholm | Vestas Wind Systems | N/A | |
| Anders Nielsen | Vestas Wind Systems | 61 | |
| Anders Pedersen | Orsted AS | N/A | |
| Anders Riis | Vestas Wind Systems | N/A | |
| Tommy Nielsen | Vestas Wind Systems | 53 | |
| Torben Bonde | Vestas Wind Systems | N/A | |
| Jakob Boss | Orsted AS | N/A | |
| Michael Ebbe | DSV Panalpina AS | 53 | |
| Paul MSc | Bavarian Nordic | 56 | |
| Kerstin Knapp | Vestas Wind Systems | 48 | |
| Michel Drie | Danske Bank AS | N/A | |
| Mikael Deigaard | Danske Bank AS | N/A | |
| Rasmus Haervig | Orsted AS | N/A | |
| Atilla Olesen | Danske Bank AS | N/A | |
| Laurence Moerlooze | Bavarian Nordic | 59 | |
| Henrik MSc | Bavarian Nordic | 58 | |
| Anders Hansen | Orsted AS | N/A | |
| Johanna Norberg | Danske Bank AS | N/A | |
| Niels Smedegaard | DSV Panalpina AS | 57 | |
| Jorgen Moeller | DSV Panalpina AS | 70 | |
Management Performance
Genmab AS Leadership Team
Elected by the shareholders, the Genmab AS's board of directors comprises two types of representatives: Genmab AS inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genmab. The board's role is to monitor Genmab AS's management team and ensure that shareholders' interests are well served. Genmab AS's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genmab AS's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Birgitte Stephensen, Senior Vice President IPR & Legal | ||
| Pernille Erenbjerg, Independent Director | ||
| Jonathan Peacock, Independent Director | ||
| Marisol Peron, Corporate Vice President Communications and Investor Relations | ||
| Birgitte MSc, Ex Officer | ||
| Daniel Bruno, Director, Employee Representative | ||
| Peter Kristensen, Director, Employee Representative | ||
| Deirdre Connelly, Independent Deputy Chairman of the Board | ||
| Judith Klimovsky, Executive Vice President Chief Development Officer | ||
| Tahamtan Ahmadi, Executive Vice President, Chief Medical Officer, Head of Experimental Medicines | ||
| Anthony Mancini, Chief Operating Officer, Executive Vice President | ||
| Paolo Paoletti, Independent Director | ||
| Judith MD, Exec Officer | ||
| Anders Pedersen, Non-Independent Director | ||
| Rolf Hoffmann, Independent Director | ||
| Anthony Pagano, Senior Vice President Global Finance and Corporate Development | ||
| Michael Bauer, Senior Vice President Head of Operations R&D | ||
| Martine Vugt, Senior Vice President - Chief of Staff | ||
| Andrew Carlsen, VP Director | ||
| Peter Ros, Sr Accounting | ||
| Jan Winkel, President and Chief Executive Officer | ||
| Mijke Zachariasse, Director, Employee Representative | ||
| Rima Nassar, Director, Employee Representative |
Genmab Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Genmab AS a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.24 | |||
| Return On Asset | 0.1 | |||
| Profit Margin | 0.47 % | |||
| Operating Margin | 0.38 % | |||
| Current Valuation | 186.33 B | |||
| Shares Outstanding | 65.96 M | |||
| Shares Owned By Institutions | 49.90 % | |||
| Price To Earning | 34.78 X | |||
| Price To Book | 7.86 X | |||
| Price To Sales | 17.00 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genmab AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Genmab Stock, please use our How to Invest in Genmab AS guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Genmab Stock analysis
When running Genmab AS's price analysis, check to measure Genmab AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab AS is operating at the current time. Most of Genmab AS's value examination focuses on studying past and present price action to predict the probability of Genmab AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab AS's price. Additionally, you may evaluate how the addition of Genmab AS to your portfolios can decrease your overall portfolio volatility.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |